InMed Pharmaceuticals Inc.
InMed Pharmaceuticals develops small molecule CB1/CB2 receptor antagonists for Alzheimer's disease, ocular, and dermatological indications.
8-KSep 18Latest SEC filing, period to Sep 16
Jul 22Latest story
Sign inSign inInMed Pharmaceuticals develops small molecule CB1/CB2 receptor antagonists for Alzheimer's disease, ocular, and dermatological indications.